Skip to main content
. 2008 Jun 28;10(6):450–458. doi: 10.1111/j.1751-7176.2008.08259.x

Figure 3.

Figure 3

Reductions from week 4 during the open‐label extension period. All changes are significantly greater than week 4 values. Note that if blood pressure (BP) control (<140/90 mm Hg) was reached, patients were discontinued from the trial at that point. 160/25, valsartan‐HCTZ; 320/25, valsartan‐HCTZ; 320/25 + 5 mg, valsartan‐HCTZ + amlodipine; 320/25 + 10 mg, valsartan‐HCTZ + amlodipine